Paraoxonase Activity and Expression Is Modulated by Therapeutics in Experimental Rat Nonalcoholic Fatty Liver Disease

Table 1

Results of serum versus liver in rat experimental fatty liver model. Fatty liver in Sprague-Dawley rats was induced by methionine-choline-deficient diet (MCDD) for 9 weeks. Rats were treated for other 6 weeks with rosiglitazone (R); metformin (M); rosiglitazone + metformin combination (R+M); ezetimibe (E); valsartan (V); rosiglitazone + metformin + valsartan in combination (R+M+V) or rosiglitazone + metformin + valsartan + ezetimibe (R+M+V+E). Malondialdehyde (MDA), Paraoxonase (PON).

	Change by %	Serum MDA	Serum PON activity	Liver MDA	Liver PON activity	Liver PON2 mRNA	Liver PON3 mRNA
MCDD	Versus control	+264 𝑃<0.01	−43 𝑃<0.05	+124 𝑃<0.01	−44 𝑃<0.01	+113 𝑃<0.05	+33 𝑃 = NS
	Versus MCDD
R	Versus control	+203 𝑃<0.01	+43 𝑃=0.01	+42 𝑃 = NS	−68 𝑃<0.01	−4 𝑃 = NS	−7 𝑃 = NS
	Versus MCDD	−15 𝑃 = NS	+148 𝑃<0.01	−37 𝑃<0.01	−40 𝑃 = NS	−55 𝑃<0.01	−30 𝑃 = NS
M	Versus control	+126 𝑃<0.01	+35 𝑃 = NS	−7 𝑃 = NS	−67 𝑃<0.01	+1 𝑃 = NS	+18 𝑃 = NS
	Versus MCDD	−37 𝑃<0.01	+134 𝑃<0.01	−58 𝑃<0.01	−39 𝑃 = NS	−53 𝑃<0.01	−11 𝑃 = NS
R+M	Versus control	+120 𝑃<0.01	+30 𝑃 = NS	+7 𝑃 = NS	−71 𝑃<0.01	+120 𝑃<0.01	+190 𝑃<0.01
	Versus MCDD	−39 𝑃<0.01	+126 𝑃<0.01	−52 𝑃<0.01	−47 𝑃<0.01	+3 𝑃 = NS	+118 𝑃<0.01
E	Versus control	+162 𝑃<0.01	+15 𝑃 = NS	+32 𝑃 = NS	−31 𝑃<0.01	+174 𝑃<0.01	+281 𝑃<0.01
	Versus MCDD	−27 𝑃<0.01	+100 𝑃<0.01	−41 𝑃<0.01	+28 𝑃 = NS	+29 𝑃=0.048	+188 𝑃<0.01
V	Versus control	+148 𝑃<0.01	+26 𝑃 = NS	+45 𝑃 = NS	−27 𝑃<0.05	+212 𝑃<0.01	+452 𝑃<0.01
	Versus MCDD	−31 𝑃<0.05	+119 𝑃<0.01	−35 𝑃<0.01	+35 𝑃 = NS	+47 𝑃<0.05	+316 𝑃<0.01
R+M+V	Versus control	+105 𝑃<0.01	+10 𝑃 = NS	−4 𝑃 = NS	−40 𝑃<0.01	+227 𝑃<0.01	+560 𝑃<0.01
	Versus MCDD	−43 𝑃<0.01	+91 𝑃<0.01	−57 𝑃<0.01	+12.5 𝑃 = NS	+54 𝑃<0.01	+397 𝑃<0.01
R+M+V+E	Versus control	+109 𝑃<0.01	+21 𝑃 = NS	−22 𝑃 = NS	−11 𝑃 = NS	+126 𝑃<0.01	+221 𝑃<0.01
	Versus MCDD	−42 𝑃<0.01	+110 𝑃<0.01	−65 𝑃<0.01	+66 𝑃<0.01	+6 𝑃 = NS	+142 𝑃<0.01